UBS: The Bull Market Is Ending, Just Not Yet

  • UBS sees indications that the U.S. bull market is reaching its late stages.
  • Increased M&A activity and volatility are typically signs of market tops.
  • Despite the warning signs, the firm sees little possibility of a recession in 2016.
  • The post-crisis U.S. bull market has now become the second-longest bull market since 1956. In a new report, UBS analyst Julian Emanuel discussed indications that the bull is nearing its end, as well as several indications that it’s not quite dead just yet.

    M&A

    Emanuel highlighted two key indicators that the bull market is now in its late stages. First, the M&A explosion in recent years is reminiscent of past market tops. He took the comparison to past tops one step further by adding that the recent merger talks between Pfizer Inc. PFE and Allergan PLC AGN are comparable to the massive mergers in past market tops, such as the AOL/Time Warner Inc TWX merger in 2000 and the Royal Bank of Scotland Group PLC RBS takeover of ABN-Amro in 2007.

    In the past, these types of blockbuster deals in market-leading sectors have been indications of imminent market tops.

    Related Link: Stocks Lower As Fed Signals Potential Rate Hike, Yet GDP Slows

    Volatility

    In addition, Emanuel noted the rise in volatility that U.S. markets have witnessed in recent months as a sign that the bull market is aging. “The cyclically high volatility regime which began in August is typical of the latter stages in bull markets; such volatility is often exacerbated by liquidation of elevated margin trading balances,” he explained.

    Time To Sell?

    Should investors be liquidating their long positions in preparation for the death of the bull?

    According to Emanuel, investors shouldn’t pull the plug quite yet. UBS has yet to see indications of the level of rising investor inflows that typically accompany market tops. In addition, all major market tops in the past 25 years have been followed by the beginning of a recession within months of the market peak. UBS’s economics team also sees “little chance” of a recession in 2016.

    Disclosure: The author holds no position in the stocks mentioned.

    Image Credit: Public Domain
    PFE Logo
    PFEPfizer Inc
    $22.980.88%

    Stock Score Locked: Want to See it?

    Benzinga Rankings give you vital metrics on any stock – anytime.

    Reveal Full Score
    Edge Rankings
    Momentum
    29.64
    Growth
    78.83
    Quality
    47.82
    Value
    31.61
    Price Trend
    Short
    Medium
    Long
    Market News and Data brought to you by Benzinga APIs
    date
    ticker
    name
    Price Target
    Upside/Downside
    Recommendation
    Firm

    Posted In:
    Comments
    Loading...